Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
PURPOSE: Randomized phase II double-blinded trial to study the effectiveness of paclitaxel and carboplatin given with either amifostine or placebo in patients with metastatic stage III or stage IV ovarian cancer or metastatic stage III or stage IV non-small cell lung cancer.
|Lung Cancer Neurotoxicity Ovarian Cancer||Drug: amifostine trihydrate Drug: carboplatin Drug: paclitaxel||Phase 2|
|Study Design:||Primary Purpose: Supportive Care|
|Official Title:||Amifostine (Ethyol) as a Protectant in Metastatic Ovarian and Non-Small Cell Lung Cancer in Paclitaxel/Carboplatin-Treated Patients: A Comparative Trial|
|Study Start Date:||May 1997|
|Study Completion Date:||October 1998|
|Primary Completion Date:||October 1998 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Determine whether patients with metastatic ovarian and non-small cell lung cancer receiving carboplatin and paclitaxel have significantly fewer neuropathic events when treated with amifostine.
OUTLINE: This is a randomized, parallel group, double blind, controlled study. Patients are randomized to either the amifostine or control group. All patients receive intravenous paclitaxel over 3 hours, followed by carboplatin once every 3 weeks for 6 cycles. Patients who are randomized to the amifostine group receive intravenous amifostine administered as a 15 minute infusion 30 minutes prior to paclitaxel therapy. Patients randomized to the control group receive an intravenous placebo solution. Patients are discontinued from the study if they have disease progression or unacceptable toxic effects after 2 cycles of treatment. Patients are followed monthly for 8 months post treatment.
PROJECTED ACCRUAL: A total of 80 patients will be accrued (40 with advanced ovarian cancer and 40 with advanced non-small cell lung cancer) within 2 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003072
|United States, California|
|Oncology Service of San Francisco General Hospital Medical Center|
|San Francisco, California, United States, 94110|
|UCSF Cancer Center and Cancer Research Institute|
|San Francisco, California, United States, 94115-0128|
|UCSF/Mt. Zion Cancer Center|
|San Francisco, California, United States, 94115|
|Veterans Affairs Medical Center - San Francisco|
|San Francisco, California, United States, 94121|
|Study Chair:||Robert J. Ignoffo, PharmD||University of California, San Francisco|